|
1
|
Zhou Z, Sehn LH, Rademaker AW, Gordon LI,
Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA,
Rodriguez MA, et al: An enhanced international prognostic index
(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated
in the rituximab era. Blood. 123:837–842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Solal-Celigny P: Follicular lymphoma
international prognostic index. Curr Treat Options Oncol.
7:270–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ardeshna KM, Smith P, Norton A, Hancock
BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G,
Hudson, et al: Long-term effect of a watch and wait policy versus
immediate systemic treatment for asymptomatic advanced-stage
non-Hodgkin lymphoma: A randomised controlled trial. Lancet.
362:516–522. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin P, Chadburn A, Christos P, Weil K,
Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, et
al: Outcome of deferred initial therapy in mantle-cell lymphoma. J
Clin Oncol. 27:1209–1213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DeVita VT Jr, Canellos GP, Chabner B,
Schein P, Hubbard SP and Young RC: Advanced diffuse histiocytic
lymphoma, a potentially curable disease. Lancet. 1:248–250. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coltman CA, Dahlberg S and Jones SE: CHOP
is curative in thirty percent of patients with large cell lymphoma:
A twelve-year Southwest oncology group follow-up. Advances in
cancer chemotherapy: Update on treatment for diffuse large cell
lymphoma. Skarin AT: Wiley; New York, NY: pp. 71–77. 1986
|
|
7
|
Johnsen AT, Tholstrup D, Petersen MA,
Pedersen L and Groenvold M: Health related quality of life in a
nationally representative sample of haematological patients. Eur J
Haematol. 83:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montgomery C, Pocock M, Titley K and Lloyd
K: Individual quality of life in patients with leukaemia and
lymphoma. Psychooncology. 11:239–243. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parker PA, Baile WF, de Moor CD and Cohen
L: Psychosocial and demographic predictors of quality of life in a
large sample of cancer patients. Psychooncology. 12:183–193. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedberg JW, Thompson CA, Trněný M,
Morschhauser F, Salles G, Reagan PM, Hertzberg M, Smolewski P,
Zhang H, Thieblemont C, et al: Health-related quality of life
(HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL)
treated with polatuzumab vedotin, rituximab, cyclophosphamide,
doxorubicin and prednisone (Pola-R-CHP) versus rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)
in the Phase III POLARIX Study. Blood. 140 (Suppl 1):S6623–S6626.
2022. View Article : Google Scholar
|
|
11
|
Ardeshna KM, Qian W, Smith P, Braganca N,
Lowry L, Patrick P, Warden J, Stevens L, Pocock CFE, Miall F, et
al: Rituximab versus a watch-and-wait approach in patients with
advanced-stage, asymptomatic, non-bulky follicular lymphoma: An
open-label randomised phase 3 trial. Lancet Oncol. 15:424–435.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brandt J, Dietrich S, Meissner J, Neben K,
Ho AD and Witzens-Harig M: Quality of life of long-term survivors
with Hodgkin lymphoma after high-dose chemotherapy, autologous stem
cell transplantation, and conventional chemotherapy. Leuk Lymphoma.
51:2012–2020. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coiffier B, Lepage E, Briere J, Herbrecht
R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G,
Gaulard P, et al: CHOP chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El Haidari RE, Anota A, Dabakuyo-Yonli TS,
Guillemin F, Conroy T, Velten M, Jolly D, Causeret S, Cuisenier J,
Graesslin O, et al: Utility values and its time to deterioration in
breast cancer patients after diagnosis and during treatments. Qual
Life Res. 31:3077–3085. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wasse SK, Mounier M, Assogba E, Rossi C,
Adnet J, Gauthier S, Girard S, Atsou KM, Dabakuyo-Yonli TS and
Maynadie M: Factors affecting health-related quality of life among
survivors of non-Hodgkin lymphoma: A population-based study.
Cancers (Basel). 15:38852023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki T, Izawa M and Okada Y: Current
trends in health insurance systems: OECD countries vs Japan. Neurol
Med Chir (Tokyo). 55:267–275. 2015. View Article : Google Scholar
|
|
17
|
Paunescu AC, Copie CB, Malak S, Gouill SL,
Ribrag V, Bouabdallah K, Sibon D, Rumpold G, Preau M, Mounier N, et
al: Quality of life of survivors 1 year after the diagnosis of
diffuse large B-cell lymphoma: A LYSA study. Ann Hematol.
101:317–332. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oerlemans S, Issa DE, van den Broek EC,
Nijziel MR, Coebergh JWW, Huijgens PC, Mols F and van de
Poll-Franse LV: Health-related quality of life and persistent
symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies
among patients with diffuse large B-cell lymphoma: Results of the
population-based PHAROS-registry. Ann Hematol. 93:1705–1715. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mounier N, Anthony S, Busson R,
Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO,
Morschhauser F, Feugier P, et al: Long-term fatigue in survivors of
non-Hodgkin lymphoma: The lymphoma study association SIMONAL
cross-sectional study. Cancer. 125:2291–2299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aogi K, Takeuchi H, Saeki T, Aiba K,
Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, et al:
Optimizing antiemetic treatment for chemotherapy-induced nausea and
vomiting in Japan: Update summary of the 2015 Japan society of
clinical oncology clinical practice guidelines for antiemesis. Int
J Clin Oncol. 26:1–17. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Herdman M, Gudex C, Lloyd A, Janssen M,
Kind P, Parkin D, Bonsel G and Badia X: Development and preliminary
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual
Life Res. 20:1727–1736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hasegawa M, Komoto S, Shiroiwa T and
Fukuda T: Formal implementation of cost-effectiveness evaluations
in Japan: A unique health technology assessment system. Value
Health. 23:43–51. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Doorduijn J, Buijt I, Holt B, Steijaert M,
Uyl-de Groot C and Sonneveld P: Self-reported quality of life in
elderly patients with aggressive non-Hodgkin's lymphoma treated
with CHOP chemotherapy. Eur J Haematol. 75:116–123. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Omachi K: JSH practical guidelines for
hematological malignancies, 2018: II. Lymphoma-overview. Int J
Hematol. 110:3–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson WH, Grossbard ML, Pittaluga S, Cole
D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J,
Gutierrez M, et al: Dose-adjusted EPOCH chemotherapy for untreated
large B-cell lymphomas: A pharmacodynamic approach with high
efficacy. Blood. 99:2685–2693. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kantarjian HM, O'Brien S, Smith TL, Cortes
J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, et al:
Results of treatment with hyper-CVAD, a dose-intensive regimen, in
adult acute lymphocytic leukemia. J Clin Oncol. 18:547–561. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Romaguera JE, Fayad L, Rodriguez MA,
Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A,
Samaniego F, Goy A, et al: High rate of durable remissions after
treatment of newly diagnosed aggressive mantle-cell lymphoma with
rituximab plus hyper-CVAD alternating with rituximab plus high-dose
methotrexate and cytarabine. J Clin Oncol. 23:7013–7023. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Markman M: Toxicities of the platinum
antineoplastic agents. Expert Opin Drug Saf. 2:597–607. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Devlen J, Maguire P, Phillips P, Crowther
D and Chambers H: Psychological problems associated with diagnosis
and treatment of lymphomas. I: Retrospective study. Br Med J (Clin
Res Ed). 295:953–954. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oerlemans S, Mols F, Nijziel MR, Zijlstra
WP, Coebergh JWW and van de Poll-Franse LV: The course of anxiety
and depression for patients with Hodgkin's lymphoma or diffuse
large B cell lymphoma: A longitudinal study of the PROFILES
registry. J Cancer Surviv. 8:555–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ohno S, Shoji A, Hatake K, Oya N and
Igarashi A: Cost-effectiveness analysis of treatment regimens with
obinutuzumab plus chemotherapy in Japan for untreated follicular
lymphoma patients. J Med Econ. 23:1130–1141. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang AL and Thomas SJ: Relationships
between depressive symptoms, other psychological symptoms, and
quality of life. Psychiatry Res. 289:1130492020. View Article : Google Scholar : PubMed/NCBI
|
